Skip to main content

Eosinophilic Granulomatosis With Polyangiitis

2
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
DepemokimabPhase 3Monoclonal Antibody1 trial
Longitudinal Study for Eosinophilic Granulomatosis With PolyangiitisN/A1 trial
Active Trials
NCT00315380Recruiting700Est. Dec 2028
NCT05263934Active Not Recruiting163Est. Oct 2026
Nippon Shinyaku
Nippon ShinyakuJapan - Kyoto
1 program
1
NS-229Phase 21 trial
Active Trials
NCT06046222Active Not Recruiting45Est. Dec 2026
GSK
GSKLONDON, United Kingdom
1 program
Longitudinal Study for Eosinophilic Granulomatosis With PolyangiitisN/A
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Longitudinal Study for Eosinophilic Granulomatosis With PolyangiitisN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
ViiV HealthcareDepemokimab
Nippon ShinyakuNS-229
ViiV HealthcareLongitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

Clinical Trials (3)

Total enrollment: 908 patients across 3 trials

NCT05263934ViiV HealthcareDepemokimab

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Start: Jul 2022Est. completion: Oct 2026163 patients
Phase 3Active Not Recruiting
NCT06046222Nippon ShinyakuNS-229

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Start: Dec 2023Est. completion: Dec 202645 patients
Phase 2Active Not Recruiting
NCT00315380ViiV HealthcareLongitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

Start: Apr 2006Est. completion: Dec 2028700 patients
N/ARecruiting

Related Jobs

Customer Engagement Manager Eosinophilic Diseases (EGPA/HES) (m/f/d)

GSKGSK
Field Worker - DEU (Munich)
2w ago

Brand Lead Eosinophilic Diseases (EGPA/HES) (m/f/d), befristet bis November 2027

GSKGSK
Munich - Office
2mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 908 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.